CGAS and hepatocellular carcinoma: The development of drugs that inhibit or promote the cGAS-STING signaling pathway has broad prospects for treating HCC, ALD, NASH, HBV, and other liver diseases, giving it a major role in basic immunology, tumor biology, and clinical treatment.